Akumentis Healthcare has launched Clasepi, a DCGI-approved prescription cannabidiol (CBD] to address seizures linked with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older.
Clasepi is reportedly the first synthetic CBD product of its kind to be made available in India. A statement from the company states, “The product with THC content below 0.1 per cent, stands out for its non-psychotropic nature. Clinical studies have demonstrated Clasepi efficacy in reducing seizures, especially in cases where conventional antiseizure medications have proven ineffective.”
Clasepi comes with important usage considerations; it is not recommended for individuals allergic to cannabidiol or any of its ingredients. Akumentis stresses the significance of adhering to healthcare providers’ prescription guidance for optimal use and safe consumption.
This information is for registered medical professionals only.